Cargando…

Fomepizole should not be used more liberally in paracetamol overdose

Fomepizole is a promising new treatment for preventing liver injury following paracetamol (acetaminophen) overdose. However, we need robust clinical trials to be performed to demonstrate its effect on clinical outcomes that are important to our patients and important to healthcare providers. Until s...

Descripción completa

Detalles Bibliográficos
Autor principal: Dear, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107630/
https://www.ncbi.nlm.nih.gov/pubmed/36471568
http://dx.doi.org/10.1111/bcp.15596
_version_ 1785026648561680384
author Dear, James W.
author_facet Dear, James W.
author_sort Dear, James W.
collection PubMed
description Fomepizole is a promising new treatment for preventing liver injury following paracetamol (acetaminophen) overdose. However, we need robust clinical trials to be performed to demonstrate its effect on clinical outcomes that are important to our patients and important to healthcare providers. Until such trials are performed, the toxicology community should learn the lessons from the COVID pandemic—potential novel therapeutic options may be theoretically appealing, but their effectiveness needs to be assessed in robust clinical trials before they are used in clinical practice.
format Online
Article
Text
id pubmed-10107630
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101076302023-04-18 Fomepizole should not be used more liberally in paracetamol overdose Dear, James W. Br J Clin Pharmacol Clinical Toxicology Pro/Con Debates Series Fomepizole is a promising new treatment for preventing liver injury following paracetamol (acetaminophen) overdose. However, we need robust clinical trials to be performed to demonstrate its effect on clinical outcomes that are important to our patients and important to healthcare providers. Until such trials are performed, the toxicology community should learn the lessons from the COVID pandemic—potential novel therapeutic options may be theoretically appealing, but their effectiveness needs to be assessed in robust clinical trials before they are used in clinical practice. John Wiley and Sons Inc. 2022-12-05 2023-02 /pmc/articles/PMC10107630/ /pubmed/36471568 http://dx.doi.org/10.1111/bcp.15596 Text en © 2022 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical Toxicology Pro/Con Debates Series
Dear, James W.
Fomepizole should not be used more liberally in paracetamol overdose
title Fomepizole should not be used more liberally in paracetamol overdose
title_full Fomepizole should not be used more liberally in paracetamol overdose
title_fullStr Fomepizole should not be used more liberally in paracetamol overdose
title_full_unstemmed Fomepizole should not be used more liberally in paracetamol overdose
title_short Fomepizole should not be used more liberally in paracetamol overdose
title_sort fomepizole should not be used more liberally in paracetamol overdose
topic Clinical Toxicology Pro/Con Debates Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107630/
https://www.ncbi.nlm.nih.gov/pubmed/36471568
http://dx.doi.org/10.1111/bcp.15596
work_keys_str_mv AT dearjamesw fomepizoleshouldnotbeusedmoreliberallyinparacetamoloverdose